Fewer than a tenth of people eligible to benefit from GLP-1 drugs like Wegovy are able to get them, caution the global health agency as it issues its first guidance on the medications.
Given in excess of 1,000,000,000 people worldwide now living with obesity, it is urging increased and just access to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that excess weight is a chronic disease that can be managed with thorough and ongoing treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key barriers to broad availability to the injections that can aid individuals in losing considerable weight, explains the body.
Weight-Loss Drug Shortage
Even in the present best projected case, the production of such drugs might only reach about 100 million people – under 10% of eligible patients, according to the health organization.
The advice urges governments and firms to expand availability, through approaches such as voluntary licensing.
A patent on the active ingredient – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026.
How Weight-Loss Injections Operate
These medications mimick a body's own hormone to reduce digestion speed, curb appetite and enhance the sense of being full so people reduce food intake.
Patients usually begin shedding pounds within a few weeks of beginning the weekly injections.
Studies indicates patients may regain a significant portion after a year of halting the drug, as their typical appetite return.
Being carrying excess weight elevates your risk for contracting diseases, like type 2 diabetes, heart disease, brain attack, and specific malignancies.
Excess weight affects people in countries worldwide and was responsible for millions of deaths worldwide in 2024, according to the WHO.
